Overview

Evaluate SAGE-547 in Female Patients With Severe Postpartum Depression

Status:
Completed
Trial end date:
2015-06-01
Target enrollment:
Participant gender:
Summary
This is an open-label proof-of-concept study designed to evaluate the safety, tolerability, PK, and efficacy of SAGE-547 Injection in adult female patients diagnosed with severe postpartum depression (PPD).
Phase:
Phase 2
Details
Lead Sponsor:
Sage Therapeutics
Treatments:
Brexanolone